Table 4:
Lineage-specific immunomarkers (modified from 43).
| Lineage category and subtypes | Immunomarkers |
|---|---|
| Lung adenocarcinoma | TTF-1, Napsin A |
| Breast carcinoma | GATA3, ER, GCDFP-15, Mamaglobin |
| Ovarian serous carcinoma | PAX-8, ER, WT1, vimentin |
| Ovarian clear cell carcinoma | pVHL, HNF-1B, KIM-1, PAX-8 |
| Endometrial adenocarcinoma | PAX-8/PAX-2, ER, vimentin |
| Endocervical adenocarcinoma | PAX-8, p16, CEA, HPV in situhybridization, loss of PAX-2 |
| Thyroid follicular cell origin | TTF-1, PAX-8, thyroglobulin |
| Thyroid medullary carcinoma | Calcitonin, TTF-1, mCEA, chromogranin |
| Salivary duct carcinoma | GATA3, AR, GCDFP-15, HER2 |
| Renal cell carcinoma, clear cell type | PAX-8/PAX-2, RCCma, pVHL, KIM-1 |
| Papillary renal cell carcinoma | P504S, RCCma, pVHL, PAX 8, KIM-1 |
| Translocation renal cell carcinoma | TFE3 |
| Upper gastrointestinal tract | CDH17, CDX2, CK20 |
| Lower gastrointestinal tract | SATB2, CDX2, CK20, CDH17 |
| Hepatocellular carcinoma | Arginase-1, CISH for albumin mRNA, Bile canalicular pattern (pCEA, CD10) |
| Intrahepatic cholangiocarcinoma | pVHL, CAIX |
| Pancreas, acinar cell carcinoma | Trypsin, chymotrypsin, lipase, elastase, BCL10 |
| Pancreas, ductal adenocarcinoma | MUC 5AC, CK17, Maspin, S100, IMP3 |
| Pancreas, neuroendocrine tumor | PR, PAX-8, PDX1, CDH17, islet-1 |
| Pancreas, solid pseudopapillary tumor | Nuclear beta-catenin, vimentin, E-cadherin-Neg, PR, CD10 |
| Prostate, adenocarcinoma | NKX3.1, PSA, PSAP, ERG |
| Urothelial carcinoma | GATA3, uroplakin II, S100P, CK5/6, p63, CK20 |
| Adrenal cortical neoplasm | SF-1, Mart-1, inhibin-a, calretinin |
| Seminoma | SALL4, LIN28, OCT4, CD117, D2-40 |
| Yolk sac tumor | SALL4, LIN28, glypican-3, AFP |
| Embryonal carcinoma | SALL4, LIN28, OCT4, NANOG, CD30, SOX2 |
| Choriocarcinoma | GATA3, b-HCG, CD10 |
| Sex cord stromal tumor | SF-1, inhibin-a, calretinin, FOXL2 |
| Thymic origin | PAX-8, p63, CD5 |
| Gastrointestinal stromal tumor | CD117, DOG1, PGDFRA |
| Solitary fibrous tumor | STAT6, CD34, Bcl2, CD99 |
| Vascular tumor | ERG, CD31, CD34, Fli-1 |
| Synovial sarcoma | TLE1, CK, nuclear beta-catenin |
| Chordoma | CK, S100, Brachyury |
| Desmoplastic small round cell tumor | CK, CD99, desmin, WT1 (N-terminus) |
| Alveolar soft part sarcoma | TFE3 |
| Rhabdomyosarcoma | Myogenin, desmin, MyoD1 |
| Smooth muscle tumor | SMA, MSA, desmin, calponin |
| Ewing sarcoma/PNET | NKX2.2, CD99, Fli-1 |
| Myxoid and round cell liposarcoma | NY-ESO-1 |
| Low-grade fibromyxoid sarcoma | MUC4 |
| Epithelioid sarcoma | CD34, loss of INI1 |
| Atypical lipomatous tumor | MDM2 (MDM2 by FISH is a more sensitive and specific test), CDK4 |
| Langerhans cell Histiocytosis | CD1a, S100, Langerin (CD207) |
| Angiomyolipoma | HMB-45, SMA, Mart-1 (S100 non-immunoreactive) |
| Myoepithelial carcinoma | Cytokeratin and myoepithelial markers (may lose INI1) |
| Myeloid sarcoma | CD43, CD34, MPO |
| Follicular dendritic cell tumor | CD21, CD35 |
| Merkel cell carcinoma | CK20 (paranuclear dot staining), MCPyV |
| Mesothelial origin | Calretinin (nuclear), WT1, D2-40, CK5/6, mesothelin, CK7, vimentin |
| Neuroendocrine origin | Chromogranin, synaptophysin, CD56 |
| Mast cell tumor | CD117, tryptase |
| Squamous cell carcinoma | p40, CK5/6, p63, SOX2 |
| Melanoma | S100, Mart-1, tyrosinase, HMB-45, MiTF, SOX10, PNL2 |